Sionna Therapeutics, Inc. (SION)
$5.85-$0.21 (-3.47%) Today
Peter A. Thompson - DirectorPeter A. Thompson - DirectorPeter A. Thompson - DirectorPeter A. Thompson - DirectorSionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 413,774 | $18.70M |
| Grant or award | 9 | 156,060 | |
| Option exercise | 2 | 20,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
51 Form 4 filings on record, the earliest from Jul 1, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Peter A. Thompson - Director | Open-market sale | Common Stock | 85,918 | $44.86 | $3.85M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 85,918 | $44.86 | $3.85M | |
| Jennifer Fitzpatrick - Officer | Option exercise | Common Stock | 10,250 | $6.11 | $63K | |
| Jennifer Fitzpatrick - Officer | Open-market sale | Common Stock | 10,250 | $43.60 | $447K | |
| Jennifer Fitzpatrick - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 10,250 | $0.00 | - | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 115,844 | $45.50 | $5.27M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 115,844 | $45.50 | $5.27M | |
| Laurie Stelzer - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
 Joanne L. Viney - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Peter A. Thompson - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Marcella K. Ruddy - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Joshua Resnick - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Harold Edward Fleming - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Paul J. Clancy - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
 Bruce Booth - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 101 | $44.49 | $4K | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 101 | $44.49 | $4K | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 48,546 | $44.61 | $2.17M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 59,767 | $44.58 | $2.66M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 184,639 | $46.22 | $8.53M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 48,546 | $44.61 | $2.17M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 59,767 | $44.58 | $2.66M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 184,639 | $46.22 | $8.53M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 52,397 | $44.68 | $2.34M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 2,948 | $44.52 | $131K | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 52,397 | $44.68 | $2.34M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 2,948 | $44.52 | $131K | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 47,814 | $44.51 | $2.13M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 235,863 | $44.64 | $10.53M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 226,906 | $45.34 | $10.29M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 47,814 | $44.51 | $2.13M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 235,863 | $44.64 | $10.53M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 226,906 | $45.34 | $10.29M | |
| Jennifer Fitzpatrick - Officer | Option exercise | Common Stock | 10,250 | $6.11 | $63K | |
| Jennifer Fitzpatrick - Officer | Open-market sale | Common Stock | 10,250 | $33.86 | $347K | |
| Jennifer Fitzpatrick - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 10,250 | $0.00 | - | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 1,890 | $44.57 | $84K | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 29,063 | $44.58 | $1.30M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 1,890 | $44.57 | $84K | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 29,063 | $44.58 | $1.30M | |
| TPG GP A, LLC - 10% Owner | Open-market sale | Common Stock | 250,000 | $40.00 | $10.00M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 33,356 | $44.55 | $1.49M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 33,356 | $44.55 | $1.49M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 900 | $44.50 | $40K | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 100 | $44.49 | $4K | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 875 | $44.49 | $39K | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 900 | $44.50 | $40K | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 100 | $44.49 | $4K | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 875 | $44.49 | $39K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Sionna Therapeutics, Inc. (SION) had 14 insider filings in the last 90 days, with the most recent on 2026-07-09. The full record for SION runs to 51 Form 4 filings, the earliest from 2025-07-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SION were filed in the last 90 days. 1 purchase is on record for this company.
5 insider sales of SION were filed in the last 90 days, totaling $18.70M.
This page tracks SION Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SION to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
